CareDx Inc
NASDAQ:CDNA

Watchlist Manager
CareDx Inc Logo
CareDx Inc
NASDAQ:CDNA
Watchlist
Price: 21.315 USD 3.42% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
CareDx Inc?
Write Note

CareDx Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CareDx Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
CareDx Inc
NASDAQ:CDNA
Depreciation & Amortization
$14.5m
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
41%
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.4B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
$5.6B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$219.7m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$469.5m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
25%
No Stocks Found

CareDx Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

CareDx Inc. is a vibrant player in the biotech landscape, navigating the intricate world of transplant medicine with a unique focus on precision diagnostics. Founded in 1998 and headquartered in South San Francisco, CareDx is deeply entrenched in the development of solutions that enhance the longevity and quality of life for organ transplant recipients. Their flagship offerings, such as AlloMap and AlloSure, are non-invasive, blood-based tests that provide critical insights into the functioning and health of transplanted organs. These tests are pivotal in assessing transplant recipients for possible organ rejection, thus presenting rapid, reliable data that may preempt irreversible damage. CareDx captures value by providing these sophisticated diagnostic tests and services to transplant centers that require cutting-edge technology to improve patient outcomes. Revenue generation for CareDx is anchored in its comprehensive commercial approach, developing partnerships with healthcare providers and transplant centers globally. By leveraging an innovative mixture of proprietary testing technology and patient-centric solutions, the company taps into the ongoing demand for improved post-transplant care. Their business model primarily revolves around offering subscription-based services that incorporate longitudinal patient monitoring and data analytics—providing healthcare professionals with a steady flow of actionable insights. CareDx further extends its revenue streams through patient management solutions and digital health offerings, enhancing its footprint in the growing transplant diagnostics market. Beyond diagnostics, CareDx's strategic aspirations see it expanding its portfolio into more integrated healthcare solutions, resonating with healthcare practitioners seeking more personalized and predictive transplant care.

CDNA Intrinsic Value
17.487 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

What is CareDx Inc's Depreciation & Amortization?
Depreciation & Amortization
14.5m USD

Based on the financial report for Sep 30, 2024, CareDx Inc's Depreciation & Amortization amounts to 14.5m USD.

What is CareDx Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
41%

Over the last year, the Depreciation & Amortization growth was 4%. The average annual Depreciation & Amortization growth rates for CareDx Inc have been 21% over the past three years , 24% over the past five years , and 41% over the past ten years .

Back to Top